CHF353.80 ROG.SW Roche (SIX) pre-market most active 11 Feb 2026: watch momentum

ROG.SW stock is trading at CHF353.80 in the pre-market on SIX and ranks among the most active Swiss names by volume. Today’s early flow shows 879073.00 shares traded versus an average of 1162890.00, signaling above-normal attention ahead of corporate updates. Key fundamentals underpinning interest include EPS 16.03, PE 21.90, and a dividend yield 2.76%. We examine why traders are active, how technical momentum supports the move, and what Meyka AI’s model and our analysts flag as the main catalysts and risks

ROG.SW stock: pre-market market snapshot

Roche Holding AG (ROG.SW) opened at CHF352.00 with a previous close of CHF353.80, day low CHF349.20 and day high CHF357.10. Market cap stands at CHF279475468338.00 and intraday volume sits at 879073.00, below the 50-day average but high for pre-market. The stock’s relative activity places it on watch lists for traders looking for short-term momentum and liquidity on SIX in Switzerland.

Fundamentals and valuation

Roche’s trailing metrics show EPS 16.03, PE 21.90, price/50-day average CHF333.72, and price/200-day average CHF284.13, reflecting a multi-month rally. Key ratios: price-to-sales 4.54, price-to-book 8.27, debt-to-equity 0.94, and dividend per share CHF9.70. Income quality and free cash flow yield (about 4.25%) support the dividend and R&D spend. These figures frame ROG.SW stock as a stable healthcare heavyweight with above-average valuation vs sector peers.

Technicals and trading signals

Momentum reads strong: RSI 73.06 indicates overbought conditions but ADX 43.57 shows a strong trend. MACD histogram is positive and short-term moving averages sit above longer-term averages, supporting continuation. Traders should note ATR 6.24 and Bollinger middle band CHF322.94 for volatility and potential intraday support. Given the most-active strategy, short-term traders may follow breakout or mean-reversion setups while managing stop levels around CHF349.20.

Meyka grade and model forecast

Meyka AI rates ROG.SW with a score out of 100: 75.28/100 (B+, BUY). This grade factors S&P 500 and sector comparisons, growth, key metrics, forecasts, and analyst sentiment. Meyka AI’s forecast model projects a monthly target of CHF374.99, a quarterly target of CHF284.39, and a yearly target of CHF244.76. These projections show a short-term implied upside but a wider longer-term range. Forecasts are model-based projections and not guarantees.

Catalysts, risks, and sector context

Catalysts: upcoming pipeline readouts, diagnostics demand, and any clarity on major launches can lift ROG.SW stock quickly. Risks: patent cliffs, margin pressure, and higher valuation multiples versus certain peers. The Healthcare sector has outpaced many sectors YTD, but Roche’s price-to-book and price-to-sales ratios are above sector averages, making valuation sensitivity a key risk. For broader context see coverage at StockAnalysis and ETF discussions that include Roche holdings on Nasdaq.

Trading strategy for most-active setups

For traders using the most-active strategy, watch intraday momentum above CHF357.10 for continuation and fades towards CHF349.20 for mean reversion entries. Position sizing should reflect Roche’s average daily volume 1162890.00 and current liquidity. Use stops near the Bollinger middle band or ATR-based levels; for swing trades consider the 50-day mean CHF333.72 as the first larger support.

Final Thoughts

Key takeaways: ROG.SW stock is a high-liquidity, high-profile healthcare name trading at CHF353.80 in the pre-market on SIX in Switzerland. Fundamentals show robust cash flow and an EPS of 16.03 with a PE of 21.90, while valuation sits above some sector peers, creating sensitivity to clinical results and macro moves. Meyka AI’s short-term model shows a near-term upside: Meyka AI’s forecast model projects a monthly price of CHF374.99, implying about 6.00% upside from today’s price, while the yearly projection of CHF244.76 implies -30.81%; forecasts are model-based projections and not guarantees. Traders focused on the most-active strategy should combine trend signals (RSI, MACD, ADX) with strict risk controls and watch corporate catalysts. Analysts should treat the Meyka grade B+ (75.28/100, BUY) as one input alongside traditional research. For active positions, set clear stop-loss rules, monitor news flow, and reassess positions if price breaches the 50-day mean CHF333.72 or the 200-day mean CHF284.13. Meyka AI provides this as AI-powered market analysis to aid decision making, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.